BRPI1011477A2 - 8-substituted quinolines and related analogues as sirtuin modulators - Google Patents
8-substituted quinolines and related analogues as sirtuin modulatorsInfo
- Publication number
- BRPI1011477A2 BRPI1011477A2 BRPI1011477A BRPI1011477A BRPI1011477A2 BR PI1011477 A2 BRPI1011477 A2 BR PI1011477A2 BR PI1011477 A BRPI1011477 A BR PI1011477A BR PI1011477 A BRPI1011477 A BR PI1011477A BR PI1011477 A2 BRPI1011477 A2 BR PI1011477A2
- Authority
- BR
- Brazil
- Prior art keywords
- related analogues
- substituted quinolines
- sirtuin modulators
- sirtuin
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15674909P | 2009-03-02 | 2009-03-02 | |
PCT/US2010/025963 WO2010101949A1 (en) | 2009-03-02 | 2010-03-02 | 8-substituted quinolines and related analogs as sirtuin modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1011477A2 true BRPI1011477A2 (en) | 2016-03-22 |
Family
ID=42709991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1011477A BRPI1011477A2 (en) | 2009-03-02 | 2010-03-02 | 8-substituted quinolines and related analogues as sirtuin modulators |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2403833A4 (en) |
JP (1) | JP2012519211A (en) |
KR (1) | KR20110128908A (en) |
CN (1) | CN102414180A (en) |
AU (1) | AU2010221417A1 (en) |
BR (1) | BRPI1011477A2 (en) |
CA (1) | CA2754058A1 (en) |
EA (1) | EA201171098A1 (en) |
IL (1) | IL214943A0 (en) |
MX (1) | MX2011009213A (en) |
WO (1) | WO2010101949A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG190603A1 (en) | 2008-05-01 | 2013-06-28 | Sirtris Pharmaceuticals Inc | Quinolines and related analogs as sirtuin modulators |
KR20110036602A (en) | 2008-07-03 | 2011-04-07 | 서트리스 파마슈티컬즈, 인코포레이티드 | Benzimidazoles and related analogs as sirtuin modulators |
AU2009295948B2 (en) | 2008-09-29 | 2013-12-05 | GlaxoSmithKline, LLC | Quinazolinone, quinolone and related analogs as sirtuin modulators |
AU2010319842A1 (en) | 2009-10-29 | 2012-05-17 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
CA2799579A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
CA2830117C (en) | 2011-03-18 | 2019-04-30 | Bayer Intellectual Property Gmbh | N-(3-carbamoylphenyl)-1h-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests |
CN102250151B (en) * | 2011-05-17 | 2013-11-06 | 中国科学院化学研究所 | 2-arimid-8-benzimidazol quinoline transition metal compound and preparation method and use thereof |
CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
RU2014120166A (en) | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | SUBSTITUTED Bicyclic AZA-HETEROCYCLES AND THEIR ANALOGUES AS SIRTUIN MODULATORS |
RU2014120168A (en) * | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | SUBSTITUTED Bicyclic Azaheterocycles and Analogs as Modulators of Sirtuin |
CA2865043A1 (en) | 2012-03-13 | 2013-09-19 | Basf Se | Fungicidal pyrimidine compounds |
KR20150085538A (en) * | 2012-11-20 | 2015-07-23 | 에프. 호프만-라 로슈 아게 | Substituted 1,6-naphthyridines |
PT2970272T (en) * | 2013-03-14 | 2019-06-05 | Merck Patent Gmbh | Glycosidase inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CA2914100A1 (en) | 2013-06-04 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof |
TWI529171B (en) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | 1,7-naphthyridine derivatives |
WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
CA2923101A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
US10172915B2 (en) | 2013-10-20 | 2019-01-08 | Duke University | Methods and compositions for activation of sirtuins with Annexin A1 peptides |
JP6112724B2 (en) * | 2013-10-31 | 2017-04-12 | 日本化薬株式会社 | 1,5-naphthyridine derivative and insecticide comprising the same as an active ingredient |
CA2929461A1 (en) * | 2013-11-12 | 2015-05-21 | F. Hoffmann-La Roche Ag | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders |
WO2015107133A1 (en) | 2014-01-20 | 2015-07-23 | Bayer Cropscience Ag | Quinoline derivatives as insecticides and acaricides |
US9688699B2 (en) | 2014-02-19 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
CN106414448B (en) | 2014-05-23 | 2019-04-19 | 活跃生物技术有限公司 | It can be used as the new compound of S100- inhibitor |
JP2017522324A (en) * | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Novel naphthyridine and isoquinoline and their use as CDK8 / 19 inhibitors |
US10752640B2 (en) | 2014-08-01 | 2020-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
SG11201701315VA (en) | 2014-08-28 | 2017-03-30 | Asceneuron Sa | Glycosidase inhibitors |
WO2016087343A1 (en) | 2014-12-02 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-a]pyridines and their use |
CN104592109A (en) * | 2015-01-19 | 2015-05-06 | 湖南华腾制药有限公司 | Method for preparing 8-bromoquinoline derivative |
MX2017010230A (en) * | 2015-02-11 | 2017-12-04 | Basilea Pharm Int Ag | Substituted mono- and polyazanaphthalene derivatives and their use. |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
CA3012560A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S.A. | Glycosidase inhibitors |
US10556902B2 (en) | 2016-02-25 | 2020-02-11 | Asceneuron Sa | Glycosidase inhibitors |
EP3419976B1 (en) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Acid addition salts of piperazine derivatives |
EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
US20220153732A1 (en) * | 2019-02-28 | 2022-05-19 | Kezar Life Sciences | Protein secretion inhibitors |
CN110964011B (en) * | 2019-12-16 | 2022-06-21 | 诚达药业股份有限公司 | Synthetic method of 8-chloro-1, 7-naphthyridine-3-formaldehyde |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
CA3188639A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
TW202302589A (en) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | Spirocyclic lactams as jak2 v617f inhibitors |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
CN117362286B (en) * | 2023-12-08 | 2024-03-12 | 清华大学 | Compounds with SIRT6 agonistic activity and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU740745B2 (en) * | 1997-12-11 | 2001-11-15 | Biochem Pharma Inc. | Antiviral compounds |
FR2827599A1 (en) * | 2001-07-20 | 2003-01-24 | Neuro3D | Treating central nervous system disorders, e.g. anxiety, depression, schizophrenia or pain, using new or known 2-substituted quinoline or quinoxaline derivatives having xanthenuric acid modulating action |
SE0103649D0 (en) * | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinoline compounds |
WO2004080463A1 (en) * | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
US7282506B2 (en) * | 2004-08-03 | 2007-10-16 | Serenex, Inc. | 2,8-disubstituted naphthyridine derivatives |
US20090069301A1 (en) * | 2005-03-03 | 2009-03-12 | Sirtris Pharmaceuticals, Inc. | Acridine and Quinoline Derivatives as Sirtuin Modulators |
WO2009106586A1 (en) * | 2008-02-28 | 2009-09-03 | Novartis Ag | Quinolines as inhibitors of farnesyl pyrophosphate synthase |
SG190603A1 (en) * | 2008-05-01 | 2013-06-28 | Sirtris Pharmaceuticals Inc | Quinolines and related analogs as sirtuin modulators |
AU2009295948B2 (en) * | 2008-09-29 | 2013-12-05 | GlaxoSmithKline, LLC | Quinazolinone, quinolone and related analogs as sirtuin modulators |
-
2010
- 2010-03-02 CA CA2754058A patent/CA2754058A1/en not_active Abandoned
- 2010-03-02 AU AU2010221417A patent/AU2010221417A1/en not_active Abandoned
- 2010-03-02 EA EA201171098A patent/EA201171098A1/en unknown
- 2010-03-02 CN CN2010800194505A patent/CN102414180A/en active Pending
- 2010-03-02 KR KR1020117023017A patent/KR20110128908A/en not_active Application Discontinuation
- 2010-03-02 MX MX2011009213A patent/MX2011009213A/en not_active Application Discontinuation
- 2010-03-02 WO PCT/US2010/025963 patent/WO2010101949A1/en active Application Filing
- 2010-03-02 JP JP2011553053A patent/JP2012519211A/en not_active Withdrawn
- 2010-03-02 BR BRPI1011477A patent/BRPI1011477A2/en not_active Application Discontinuation
- 2010-03-02 EP EP10749227A patent/EP2403833A4/en not_active Withdrawn
-
2011
- 2011-09-01 IL IL214943A patent/IL214943A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2403833A1 (en) | 2012-01-11 |
EA201171098A1 (en) | 2012-04-30 |
IL214943A0 (en) | 2011-11-30 |
JP2012519211A (en) | 2012-08-23 |
CA2754058A1 (en) | 2010-09-10 |
AU2010221417A1 (en) | 2011-09-22 |
MX2011009213A (en) | 2011-12-14 |
WO2010101949A1 (en) | 2010-09-10 |
KR20110128908A (en) | 2011-11-30 |
EP2403833A4 (en) | 2012-08-29 |
CN102414180A (en) | 2012-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1011477A2 (en) | 8-substituted quinolines and related analogues as sirtuin modulators | |
BRPI0913117A2 (en) | imidazopyridine and related analogues as sirtuin modulators | |
BRPI0919389A2 (en) | chromone analogues as sirtuin modulators | |
BRPI0914006A2 (en) | benzimidazoles and related analogues as sirtuin modulators | |
BRPI0922180A2 (en) | insoindolinone and related analogues as modulators of sirtuin | |
BRPI0919625A2 (en) | pyriridine, bicyclic pyridine and related analogues as sirtuin modulators | |
BRPI0922597A8 (en) | phthalazinone and related analogues as sirtuin modulators | |
BR112014009531A8 (en) | substituted bicyclic azaheterocycles and analogues as sirtuin modulators | |
BR112014009348A2 (en) | bicyclic substituted azaheterocycles and analogues as sirtuin modulators | |
BRPI1011694A2 (en) | category similators | |
IL208997A0 (en) | Quinolines and related analogs as sirtuin modulators | |
BRPI0915867A2 (en) | 4-phenoxymethylpiperidines as modulators of gpr119 activity | |
BRPI1014982A2 (en) | suspension device | |
SG10201402723QA (en) | Flavonoid hydrogel | |
DK2246017T3 (en) | Absorbent object | |
BRPI1011310A2 (en) | aircraft | |
BRPI1008744A2 (en) | hydrotreating of cabohydrates | |
BR112012010242A2 (en) | heteroarylpiperidine and heteroarylpiperazine derivatives | |
BRPI1007368A2 (en) | misting device | |
BRPI1009428A2 (en) | Substituted 3-aminoisoxazolopyridine as kcnq2 / 3 modulators | |
FR2947857B1 (en) | DESHUILEUR ARRANGEMENT | |
BRPI1008963A2 (en) | Substituted 2-mercapto-3-aminopyridine as kcnq2 / 3 modulators | |
BR112012000654A2 (en) | suspension structures | |
DK2267242T3 (en) | replacement Console | |
DE112010001133B8 (en) | lubricator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |